Not long after leaving GSK, Andrew Witty dips toes back into water

pharmafile | July 14, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andrew Witty, G1 Therapeutics, GSK, biotech, drugs, pharma, pharmaceutical 

Only a short while after leaving his position as CEO of GSK, it seems Andrew Witty cannot resist getting back into the industry, as he takes up a board position at newly-fledged biotech, North Carolina-based, G1 Therapeutics.

The appointment is a massive coup for the biotech that recently completed a $105 million IPO and the addition of industry-veteran to its board will only increase confidence in the company.

The biotech’s lead candidate is a CDK4/6 inhibitor that is designed to be used in combination with chemotherapy for small-cell lung cancer and triple negative breast cancer. Data on the drug’s performance in Phase 2 trials are expected to be released next year.

“We are thrilled to welcome Andrew to our board of directors,” said Mark Velleca, CEO of G1 Therapeutics. “Andrew led and oversaw the development, commercialization, and global market access for several leading pharmaceutical products at GSK. We anticipate leveraging his wealth of industry experience as we advance G1’s portfolio of potential best-in-class and first-in-class therapies.”

Witty’s experience will certainly be a bonus, after 30 year journey at GSK that resulted in him being appointed CEO and saw him lead the company in a notable shift towards ethical practices, including a drive to increase access to medicines in lower-income countries.

Witty will balance his new role with his position as a Director of Singapore Economic Development Board and his position on the Imperial College Commercialisation Advisory Board. He is also the Chancellor of the University of Nottingham.

“As someone who is passionate about the development of new and meaningful medicines, I am delighted to join the G1 board of directors,” said Witty. “The encouraging early clinical data generated by G1’s CDK4/6 inhibitors support their potential to improve patient outcomes in multiple oncology indications. I look forward to working with the G1 team at this exciting time of corporate growth.”

Related Content


GSK shares data from global shingles survey

GSK has announced data from its new global survey about shingles. The data suggests that …


GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …

GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trials 

GSK has announced that in 2024 it intends to start phase 3 trials of a …

Latest content